{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:31:07Z","timestamp":1654648267460},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12328-020-01154-z","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T19:03:46Z","timestamp":1592420626000},"page":"902-906","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy"],"prefix":"10.1007","volume":"13","author":[{"given":"Suguru","family":"Hirose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Ishige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"Yamaura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneo","family":"Mizui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichinosuke","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,15]]},"reference":[{"key":"1154_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1154_CR2","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907\u201317.","journal-title":"Lancet"},{"key":"1154_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, SHARP Investigators Study Group, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med."},{"key":"1154_CR4","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/hep.29515","volume":"67","author":"J Rimola","year":"2018","unstructured":"Rimola J, D\u00edaz-Gonz\u00e1lez \u00c1, Darnell A, et al. Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. Hepatology. 2018;67:612\u201322.","journal-title":"Hepatology"},{"key":"1154_CR5","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, et al. BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099\u2013109.","journal-title":"Cancer Res"},{"key":"1154_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"1154_CR7","doi-asserted-by":"publisher","first-page":"12581","DOI":"10.3748\/wjg.v20.i35.12581","volume":"20","author":"M Yada","year":"2014","unstructured":"Yada M, Masumoto A, Motomura K, et al. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol. 2014;20:12581\u20137.","journal-title":"World J Gastroenterol"},{"key":"1154_CR8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s12094-016-1537-6","volume":"19","author":"A Lamarca","year":"2017","unstructured":"Lamarca A, Abdel-Rahman O, Salu I, et al. Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib. Clin Transl Oncol. 2017;19:364\u201372.","journal-title":"Clin Transl Oncol"},{"key":"1154_CR9","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1634\/theoncologist.2011-0105","volume":"16","author":"T Yau","year":"2011","unstructured":"Yau T, Yao TJ, Chan P, et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist. 2011;16:1270\u20139.","journal-title":"Oncologist"},{"key":"1154_CR10","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1002\/cncr.25257","volume":"116","author":"YY Shao","year":"2010","unstructured":"Shao YY, Lin ZZ, Hsu C, et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010;116:4590\u20136.","journal-title":"Cancer"},{"key":"1154_CR11","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/hep.25956","volume":"57","author":"T Arao","year":"2013","unstructured":"Arao T, Ueshima K, Matsumoto K, et al. FGF3\/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology. 2013;57:1407\u201315.","journal-title":"Hepatology"},{"key":"1154_CR12","doi-asserted-by":"publisher","first-page":"49091","DOI":"10.18632\/oncotarget.10077","volume":"7","author":"M Kaibori","year":"2016","unstructured":"Kaibori M, Sakai K, Ishizaki M, et al. Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. Oncotarget. 2016;7:49091\u20138.","journal-title":"Oncotarget"},{"key":"1154_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000341259","volume":"5","author":"H Mizukami","year":"2012","unstructured":"Mizukami H, Kagawa T, Arase Y, et al. Complete response after short-term sorafenib treatment in a patient with lymph node metastasis of hepatocellular carcinoma. Case Rep Oncol. 2012;5:380\u20134.","journal-title":"Case Rep Oncol"},{"key":"1154_CR14","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.2169\/internalmedicine.52.9340","volume":"52","author":"A Hagihara","year":"2013","unstructured":"Hagihara A, Teranishi Y, Kawamura E, et al. A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma. Intern Med. 2013;52:1589\u201392.","journal-title":"Intern Med"},{"key":"1154_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/1477-7819-11-171","volume":"11","author":"S Kermiche-Rahali","year":"2013","unstructured":"Kermiche-Rahali S, Di Fiore A, Drieux F, et al. Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib. World J Surg Oncol. 2013;11:171.","journal-title":"World J Surg Oncol"},{"key":"1154_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3892\/ol.2013.1664","volume":"7","author":"K Shiozawa","year":"2014","unstructured":"Shiozawa K, Watanabe M, Ikehara T, et al. Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report. Oncol Lett. 2014;7:50\u20132.","journal-title":"Oncol Lett"},{"key":"1154_CR17","doi-asserted-by":"publisher","first-page":"14505","DOI":"10.3748\/wjg.v20.i39.14505","volume":"20","author":"HB Huan","year":"2014","unstructured":"Huan HB, Lau WY, Xia F, et al. Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. World J Gastroenterol. 2014;20:14505\u20139.","journal-title":"World J Gastroenterol"},{"key":"1154_CR18","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/hepr.12297","volume":"44","author":"S Shiba","year":"2014","unstructured":"Shiba S, Okusaka T, Ikeda M, et al. Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. Hepatol Res. 2014;44:1268\u201376.","journal-title":"Hepatol Res"},{"key":"1154_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40001-015-0085-9","volume":"20","author":"D Liu","year":"2015","unstructured":"Liu D, Liu A, Peng J, et al. Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib. Eur J Med Res. 2015;20:12.","journal-title":"Eur J Med Res"},{"key":"1154_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000438746","volume":"9","author":"E Katafuchi","year":"2015","unstructured":"Katafuchi E, Takami Y, Wada Y, et al. Long-term maintenance of complete response after sorafenib treatment for multiple lung metastases from hepatocellular carcinoma. Case Rep Gastroenterol. 2015;9:285\u201390.","journal-title":"Case Rep Gastroenterol"},{"key":"1154_CR21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s12328-015-0594-7","volume":"8","author":"T Kitajima","year":"2015","unstructured":"Kitajima T, Hatano E, Mitsunori Y, et al. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection. Clin J Gastroenterol. 2015;8:300\u20135.","journal-title":"Clin J Gastroenterol"},{"key":"1154_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3350\/cmh.2016.0070","volume":"23","author":"TS Kim","year":"2017","unstructured":"Kim TS, Kim JH, Kim BH, et al. Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review. Clin Mol Hepatol. 2017;23:340\u20136.","journal-title":"Clin Mol Hepatol"},{"key":"1154_CR23","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/hepr.12698","volume":"46","author":"N Nakano","year":"2016","unstructured":"Nakano N, Kawaoka T, Aikata H, et al. Complete response to short-term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases. Hepatol Res. 2016;46:1402\u20138.","journal-title":"Hepatol Res"},{"key":"1154_CR24","first-page":"403","volume":"25","author":"Q Li","year":"2006","unstructured":"Li Q, Xu B, Fu L, et al. Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma. J Exp Clin Cancer Res. 2006;25:403\u20139.","journal-title":"J Exp Clin Cancer Res"},{"key":"1154_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1055\/s-0038-1673621","volume":"38","author":"YY Lin","year":"2018","unstructured":"Lin YY, Tan CT, Chen CW, et al. Immunomodulatory effects of current targeted therapies on hepatocellular carcinoma: implication for the future of immunotherapy. Semin Liver Dis. 2018;38:379\u201388.","journal-title":"Semin Liver Dis"},{"issue":"15","key":"1154_CR26","doi-asserted-by":"publisher","first-page":"e130116","DOI":"10.1172\/jci.insight.130116","volume":"4","author":"SG Kalathil","year":"2019","unstructured":"Kalathil SG, Hutson A, Barbi J, et al. Augmentation of IFN-\u03b3+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. JCI Insight. 2019;4(15):e130116.","journal-title":"JCI Insight"},{"key":"1154_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/jso.2930170302","volume":"17","author":"WH Cole","year":"1981","unstructured":"Cole WH. Efforts to explain spontaneous regression of cancer. J Surg Oncol. 1981;17:201\u20139.","journal-title":"J Surg Oncol"},{"key":"1154_CR28","first-page":"1475","volume":"40","author":"T Iwanaga","year":"2013","unstructured":"Iwanaga T. Studies on cases of spontaneous regression of cancer in Japan in 2011, and of hepatic carcinoma, lung cancer and pulmonary metastases in the world between 2006 and 2011. Gan To Kagaku Ryoho. 2013;40:1475\u201387.","journal-title":"Gan To Kagaku Ryoho"},{"key":"1154_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/bmj.300.6725.641","volume":"300","author":"G Tocci","year":"1990","unstructured":"Tocci G, Conte A, Guarascio P, et al. Spontaneous remission of hepatocellular carcinoma after massive gastrointestinal haemorrhage. BMJ. 1990;300:641\u20132.","journal-title":"BMJ"},{"key":"1154_CR30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10147-006-0591-4","volume":"11","author":"S Kondo","year":"2006","unstructured":"Kondo S, Okusaka T, Ueno H, et al. Spontaneous regression of hepatocellular carcinoma. Int J Clin Oncol. 2006;11:407\u201311.","journal-title":"Int J Clin Oncol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01154-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-020-01154-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01154-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T23:20:38Z","timestamp":1623712838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-020-01154-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,15]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1154"],"URL":"https:\/\/doi.org\/10.1007\/s12328-020-01154-z","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,15]]},"assertion":[{"value":"3 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ichinosuke Hyodo received lecture fees from company Taiho, Chugai, Daiichi-Sankyo and Yakult-Honsha. Suguru Hirose, Kazunori Ishige, Masamichi Yamaura, Tsuneo Mizui, Yoshiki Komatsu, Masaomi Nagase, Masashi Sato, Junji Hattori, Masato Endo, Naoyuki Hasegawa, and Kuniaki Fukuda declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}